The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

BACKGROUND: Fingolimod (Gilenya®) is an oral medication for patients with highly active relapsing-remitting Multiple Sclerosis (RRMS). Clinical trials and post-marketing experience on more than 114,000 patients have established a detailed safety profile. Total patient exposure now exceeds 195,000 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Kern, Raimar, Cornelissen, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472406/
https://www.ncbi.nlm.nih.gov/pubmed/26084334
http://dx.doi.org/10.1186/s12883-015-0342-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472406/
https://www.ncbi.nlm.nih.gov/pubmed/26084334
http://dx.doi.org/10.1186/s12883-015-0342-0

Ejemplares similares